



- (51) International Patent Classification:
A01N 1/00 (2006.01) *A01N 1/02* (2006.01)
- (21) International Application Number:
PCT/US2013/078052
- (22) International Filing Date:
27 December 2013 (27.12.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/848,350 31 December 2012 (31.12.2012) US
61/848,349 31 December 2012 (31.12.2012) US
- (71) Applicant: SOMAHLUTION, LLC [US/US]; 225 Chimney Corner Lane, Jupiter, FL 33458 (US).
- (72) Inventors: SURYAN, Mahendra; 8066 Mariposa Grove Circle, Wellington, FL 33411 (US). MENON, Satish; 4850 Chancellor Drive, #11, Jupiter, FL 33458 (US).
- (74) Agents: ARDIZZONE, Timothy D. et al.; Wood, Herron & Evans, LLP, 2700 Carew Tower, 441 Vine Street, Cincinnati, OH 45202-2917 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: ORGAN AND TISSUE PRESERVATION FORMULATIONS WITH INCREASED STABILITY AND SHELF LIFE




FIG. 1

(57) Abstract: Organ and tissue preservation formulations with improved stability shelf life are provided by separating the formulation into a first solution having a pH of at least 7 and a second solution having a pH of less than 7. The first solution includes components with improved stability when stored at a pH of 7 or above, and the second solution includes components with improved stability when stored at a pH below 7. The first solution includes water, a balanced salt solution, a sugar, adenosine, orotic acid, malic acid, L-carnitine, and insulin. The second solution includes water, an antioxidant such as ascorbic acid, a cellular reducing agent such as reduced glutathione, L-citrulline, creatine monohydrate, L-carnosine, and L-arginine. During use, the first and second solutions are mixed to form a final formulation that can be used at a physiological pH to preserve the function of the tissue or organ.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*